TD Asset Management Inc Has $12.15 Million Position in Structure Therapeutics Inc. Sponsored ADR $GPCR

TD Asset Management Inc grew its holdings in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) by 384.0% in the fourth quarter, HoldingsChannel.com reports. The fund owned 174,674 shares of the company’s stock after acquiring an additional 138,588 shares during the quarter. TD Asset Management Inc’s holdings in Structure Therapeutics were worth $12,149,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. CWM LLC grew its holdings in Structure Therapeutics by 35.2% during the 4th quarter. CWM LLC now owns 480 shares of the company’s stock worth $33,000 after acquiring an additional 125 shares during the period. EverSource Wealth Advisors LLC grew its holdings in Structure Therapeutics by 530.0% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the company’s stock worth $30,000 after acquiring an additional 901 shares during the period. State of Wyoming acquired a new stake in Structure Therapeutics during the 2nd quarter worth about $28,000. Banque Cantonale Vaudoise acquired a new stake in Structure Therapeutics during the 4th quarter worth about $205,000. Finally, ProShare Advisors LLC acquired a new stake in Structure Therapeutics during the 4th quarter worth about $206,000. 91.78% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. HC Wainwright decreased their target price on Structure Therapeutics from $114.00 to $100.00 and set a “buy” rating for the company in a research report on Monday, March 16th. Wolfe Research assumed coverage on Structure Therapeutics in a research report on Thursday, March 26th. They issued a “peer perform” rating for the company. William Blair reaffirmed an “outperform” rating on shares of Structure Therapeutics in a research report on Monday, March 16th. Canaccord Genuity Group assumed coverage on Structure Therapeutics in a research report on Monday, April 27th. They issued a “buy” rating and a $101.00 target price for the company. Finally, Wall Street Zen lowered Structure Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Three analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Structure Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $109.25.

Structure Therapeutics Price Performance

Shares of Structure Therapeutics stock opened at $37.77 on Tuesday. Structure Therapeutics Inc. Sponsored ADR has a one year low of $15.80 and a one year high of $94.90. The firm has a market capitalization of $2.68 billion, a price-to-earnings ratio of -43.41 and a beta of -1.35. The business has a 50-day simple moving average of $44.03 and a 200 day simple moving average of $57.13.

Structure Therapeutics (NASDAQ:GPCR) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.04. On average, sell-side analysts expect that Structure Therapeutics Inc. Sponsored ADR will post -1.64 EPS for the current year.

Structure Therapeutics Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.